Skip to Content
Stanford Medicine Dermatology

Stanford Medicine

Explore Stanford Medicine

  • Health Care
    • Find a doctor

    • Adult-care doctor
    • Pediatrician or pediatric specialist
    • Obstetrician
    • Clinics & Services

    • Adult care
    • Pediatric care
    • Obstetrics
    • Clinical trials
    • Locations

    • Stanford Health Care
    • Stanford Children's Health
    • Emergency Department
    • Dial 911 in the event of a medical emergency

    Explore Health Care

    Learn how we are healing patients through science & compassion

    Back
  • Research
    • Basic science departments
    • Clinical science departments
    • Institutes
    • Research centers
    • See full directory
    • Research Resources

    • Research administration
    • Academic profiles
    • Clinical trials
    • Funding opportunities
    • See all
    • Professional Training

    • Postdoctoral scholars
    • Clinical research fellows

    Research News

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Neuroscientist Michelle Monje awarded MacArthur 'genius grant'

    Explore Research

    Learn how we are fueling innovation

    Back
  • Education
    • MD program
    • PA Programs
    • PhD programs
    • Masters programs
    • Continuing Medical Education
    • Postdoctoral scholars
    • Residencies & fellowships
    • High School & Undergraduate Programs
    • See all
    • Education Resources

    • Academic profiles
    • School Administration
    • Basic science departments
    • Clinical science departments
    • Alumni services
    • Faculty resources
    • Diversity programs
    • Lane Library
    • Student resources

    Education News

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Alice L. Walton School of Medicine and Stanford Medicine host AI conference on community health

    Explore Education

    Learn how we empower tomorrow's leaders

    Back
  • Give

    Support Stanford Medicine

    • Support teaching, research, and patient care.

    • Ways to give
    • Why giving matters
    • Make a gift online

    Support Children's Health

    • Support Lucile Packard Children's Hospital Stanford and child and maternal health

    • Ways to give
    • How your gift helps
    • Make an online gift
    Back
  • About
    • About us
    • News
    • Contacts
    • Maps & directions
    • Leadership
    • Vision
    • Diversity
    • Global health
    • Community engagement
    • Events
    • How you can help

    Stanford School of Medicine

    Stanford Health Care

    Stanford Children's Health

    Back
  • Site Search
  • Faculty

    Faculty

    • All Affiliated Faculty
    • Open Faculty Positions
  • Education

    Education

    • Residency

      Residency

      • Message from Program Directors
      • Residency Program Leadership
      • Research and Elective Opportunities
      • Subspecialties
      • Curriculum
      • Residents
      • Resident Life
      • Resident Wellness
      • Application Process
      • Resources
      • Global Health
      • Clinical Sites
      • Salary & Benefits
    • Medical Students
    • Fellowship

      Fellowship

      • Post-Doctoral Research Fellowship
      • Peds Research Fellowship
      • Melanoma-focused Research Fellowship
    • Visiting Rotations & Observerships
    • Grand Rounds

      Grand Rounds

      • Information for Patients
      • Information for Doctors
      • Directions
    • Rodan + Fields Lecture
    • COVID as a Catalyst Webinar
    • Marvin Karasek Lecture
  • Research

    Research

    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Genetic Testing for DEB
        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Clinical Trials
    • Skin Cancer Brochure
    • Epithelial Biology Program
    • Stanford EB Research

      Stanford EB Research

      • Current Studies

        Current Studies

        • Serlopitant for Itch in EB
        • Characteristics of RDEB Patients
        • EB 101 for RDEB
        • Intravenous C7 for RDEB
        • Topical Gene Therapy for RDEB
        • Injected Gene Therapy for RDEB
        • Exon Skipping Therapy
        • EBCRC
        • RDEB Wound Natural History
        • Stanford and UMCG Cannabinoid Survey
        • Drug Repurposing
      • Prior Clinical Studies
      • Pre-Clinical Studies to Date
      • Meet the Clinical Research Team
      • Stanford EB Publications
      • In the Press
    • Stanford Skin Innovation and Interventional Research Group
    • Translational AI in Dermatology (TRAIND)
  • Resources

    Resources

    • Department History
    • Photo Instruction for Video Visits
    • Epithelial Biology Program
    • Genetic Skin Disease Center

      Genetic Skin Disease Center

      • Epidermolysis Bullosa Clinic

        Epidermolysis Bullosa Clinic

        • EB FAQs
        • EB Clinic Visits
        • EB Wound Care Videos
        • EB Resources
        • EB People
      • Our Team
      • Clinic Appointments and Referrals
      • Support Our Research
      • Contact Us
    • In The Spotlight Archive
    • Related Links
    • Clinical Schedules
    • Newsletter
    • Resident On-Call Schedule
  • Patient Care

    Patient Care

    • All Clinics
    • Directions to SMOC
    • Subspecialties
  • Contact

    Contact

    • Administrative Staff
  • SUPPORT

Clinical Trials Unit

Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit. 

The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications.  The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments.  New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies. 

Skin Aging Studies

We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.

Nonmelanoma Skin Cancer

Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.

Acne Rosecea

This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.

Contact

For more information, please email dermtrials@stanford.edu

Featured Clinical Trials

No trials match your search ""

Psoriasis Clinical Trials

  • Renal Denervation SPYRAL OFF

    Trial for patients on one or no medications with SBP 150-180 mmHg - this trial is designed to see if renal denervation can be used as a primary option for hypertension (HTN).

    Follow up: Patients in the SPYRAL HTN-OFF MED study will be followed every 2 weeks for 3 months then at 6, 12, 24, and 36 months.

    Renal Denervation: The procedure is called renal denervation, which uses a medical device catheter to deliver low-level radiofrequency (RF) energy through the wall of a blood vessel (renal artery) to the kidney.  This procedure may decrease the kidneys’ release of hormones that raises the blood pressure, which may in turn decrease high blood pressure.

    Investigator

    • David Lee, MD
    Now accepting new patients View Details
  • Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

    Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment.

    There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

    Investigators

    • Susan R. Hintz, M.D., M.S. Epi.
    • Lynn Peng
    • Valerie Chock
    Now accepting new patients View Details
  • Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - a Randomized Clinical Trial in Acute Kidney Injury

    This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to CKRT alone (standard of care). This study is further intended to determine whether SCD therapy will reduce the duration of maintenance dialysis secondary to AKI. This study will enroll approximately 200 subjects across 30 US sites. Participants will be patients in an intensive care unit (ICU) setting with a diagnosis of AKI requiring CKRT.

    Investigators

    • Glenn M. Chertow
    • Vikram Fielding-Singh
    Now accepting new patients View Details
  • Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS

    This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a condition characterized by the abrupt, dramatic onset of obsessive compulsive disorder (OCD) and/or eating restriction accompanied by equally abrupt and severe co-morbid neuropsychiatric symptoms, which include anxiety, emotional lability, depression, irritability, aggression, oppositionality, deterioration in school performance, behavioral (developmental) regression, sensory amplification, movement abnormalities, sleep disturbance, and urinary frequency. PANS is thought to be caused by infection, inflammation, or alternate triggers that is associated with a brain response that leads to these symptoms. The purpose of this study is to examine specific neurologic, immunologic, rheumatologic, and genomic, components in children with the acute-onset of psychiatric symptoms. This research may begin to uncover a much larger story of autoimmune processes that are involved in psychiatric disorders of childhood. By better understanding the etiologic components of psychiatric phenomenon, future treatments may be better targeted to underlying causes.

    Investigator

    • Jennifer Frankovich
    Now accepting new patients View Details
  • NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

    Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.

    Investigators

    • Amelia Claire Watkins
    • Jason T. Lee, MD
    Now accepting new patients View Details
  • REHAB Fontan Failure: A Trial of Cardiac Rehabilitation

    The goal of this clinical trial is to compare the impact of cardiac rehabilitation on Fontan failure patients' exertional tolerance, frailty, and quality of life.

    1. Among patients with Fontan failure, will cardiac rehabilitation increase average daily steps compared to usual care?2. Among patients with Fontan failure, will cardiac rehabilitation improve exertional tolerance (as measured by cardiopulmonary exercise testing), frailty, and self-reported quality of life metrics compared to usual care?

    Investigator

    • Daniel Clark, MD, MPH
    Now accepting new patients View Details
  • Niclosamide in Pediatric Patients With Relapsed and Refractory AML

    Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

    Investigators

    • Adam Frymoyer
    • Norman J. Lacayo, MD
    • Kathleen M. Sakamoto
    Now accepting new patients View Details
  • HEAL-IST IDE Trial

    Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.

    Investigators

    • Albert "A.J." Rogers, MD, MBA, FAHA
    • Nitish Badhwar
    Now accepting new patients View Details
  • Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

    The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

    Investigator

    • Kevin M. Alexander, MD, FACC, FHFSA
    Now accepting new patients View Details
  • Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

    This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).

    The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

    Investigator

    • John W. Day, MD, PhD
    Now accepting new patients View Details
  • Prostate Cancer Upgrading Reference Set

    Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence of high grade cancer at time of prostatectomy (removal of prostate) among patients with a low grade cancer diagnosis at time of biopsy.

    Investigator

    • James D. Brooks
    Now accepting new patients View Details
  • Nerve Transfers Plus Electrical Stimulation to Improve Hand Function in Cervical Spinal Cord Injury

    The goal of this prospective observational study is to determine whether brief intraoperative electrical stimulation and temporary postoperative electrical stimulation improve motor and/or pain outcomes for patients with cervical spinal cord injury undergoing standard of care nerve transfer surgery to improve hand function.

    The main hypotheses include:

    Hypothesis #1: Brief intraoperative electrical stimulation of the donor nerves will result in improved motor outcomes (hand function) compared to standard nerve transfer surgery in patients with cervical spinal cord injuries.

    Hypothesis #2: Placement of a temporary peripheral nerve stimulator for 60 days of postoperative electrical stimulation will result in improved pain outcomes compared to standard nerve transfer surgery in patients with cervical spinal cord injuries.

    Researchers will prospectively enroll patients with cervical spinal cord injury and no hand function who will undergo standard of care nerve transfer surgery combined with standard of care brief intraoperative electrical stimulation and temporary postoperative electrical stimulation. Motor and pain outcomes will be compared to a retrospective group of patients who underwent nerve transfer surgery without intraoperative or postoperative electrical stimulation.

    Participants will receive standard medical care (nothing experimental) as part of this study. Participants will:

    * Have a preoperative assessment including physical examination, electrodiagnostic studies, functional electrical stimulation, and will complete questionnaires assessing function and quality of life* Agree upon a surgical plan, including the specific nerve transfers to be performed and whether to include brief intraoperative electrical stimulation and/or temporary postoperative electrical stimulation before being considered for enrollment in the study* Will undergo standard of care nerve transfer surgery, with at least one nerve transfer targeting improvement in hand function and will receive brief intraoperative electrical stimulation of the donor nerves and placement of a temporary peripheral nerve stimulator* Will follow-up with the surgeon 3, 6, 12, 24, and 36 months after the surgery* Will have a physical examination and will complete questionnaires at the postoperative visits* Will participate in hand therapy following the operation* Will be eligible for placement of a permanent peripheral nerve stimulator, depending on response to the temporary peripheral nerve stimulator.

    Investigator

    • Thomas J. Wilson
    Now accepting new patients View Details
  • MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans with Severe Posttraumatic Stress Disorder

    In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) in the treatment of posttraumatic stress disorder (PTSD). Through a randomized comparison of MDMA-aCPT versus Cognitive Processing Therapy (CPT), a VA gold standard treatment for PTSD, the proposed study will set the stage for understanding the potential use and application of MDMA-aCPT for PTSD within the VA system.

    Investigator

    • Trisha Suppes, MD, PhD
    Now accepting new patients View Details
  • Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

    This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).

    Investigator

    • Catherine Aftandilian
    Now accepting new patients View Details
  • North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

    The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.

    Investigator

    • Gregory Enns
    Now accepting new patients View Details
  • Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

    The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

    Now accepting new patients View Details
  • Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

    While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer typically present with different molecular profiles from that of smokers, which results in prognostic and therapeutic implications. Molecular changes in NSCLC that have therapeutic significance include mutations in the epidermal growth factor receptor (EGFR) and rearrangements in the anaplastic lymphoma kinase (ALK) gene. These driver mutations typically are present in lung tumors found in never or light smokers.

    The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3 months respectively. Results from the POINTBREAK trial demonstrated that carboplatin + pemetrexed + bevacizumab is an alternative option to carboplatin + paclitaxel + bevacizumab, with comparable survival but less toxicity. In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. The PD-1 inhibitor nivolumab and the PD-L1 inhibitor atezolizumab have shown prolonged survival in comparison to docetaxel in patients who previously progressed with chemotherapy, irrespective of PD-L1 expression. Thus, this study combines immunotherapeutic agent atezolozumab with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin and pemetrexed).

    Investigator

    • Heather Wakelee
    Now accepting new patients View Details
  • Preimplantation Genetic Testing in Women of Advanced Maternal Age

    The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.

    Investigator

    • Ruth Lathi, M.D.
    Now accepting new patients View Details
  • Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health

    In the U.S. it is recommended that children consume whole cow's milk (3.5% fat) from ages 1 to 2 years to support rapid early growth and brain development, and then at age 2 years transition to low-fat (1%) or non-fat milk to reduce saturated fat and calorie intake. To date, few studies have examined the optimal milk type for children to prevent obesity. This randomized controlled trial will evaluate the effect of consumption of whole versus 1% milk on child adiposity.

    Investigator

    • Anisha I Patel
    Now accepting new patients View Details
  • Imaging Synapses With [11C] UCB-J in the Human Brain

    The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by \[11C\]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.

    Investigator

    • Jong H. Yoon
    Now accepting new patients View Details
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next

Dermatology Clinical Trials

  • Renal Denervation SPYRAL OFF

    Trial for patients on one or no medications with SBP 150-180 mmHg - this trial is designed to see if renal denervation can be used as a primary option for hypertension (HTN).

    Follow up: Patients in the SPYRAL HTN-OFF MED study will be followed every 2 weeks for 3 months then at 6, 12, 24, and 36 months.

    Renal Denervation: The procedure is called renal denervation, which uses a medical device catheter to deliver low-level radiofrequency (RF) energy through the wall of a blood vessel (renal artery) to the kidney.  This procedure may decrease the kidneys’ release of hormones that raises the blood pressure, which may in turn decrease high blood pressure.

    Investigator

    • David Lee, MD
    Now accepting new patients View Details
  • Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

    Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment.

    There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

    Investigators

    • Susan R. Hintz, M.D., M.S. Epi.
    • Lynn Peng
    • Valerie Chock
    Now accepting new patients View Details
  • Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - a Randomized Clinical Trial in Acute Kidney Injury

    This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to CKRT alone (standard of care). This study is further intended to determine whether SCD therapy will reduce the duration of maintenance dialysis secondary to AKI. This study will enroll approximately 200 subjects across 30 US sites. Participants will be patients in an intensive care unit (ICU) setting with a diagnosis of AKI requiring CKRT.

    Investigators

    • Glenn M. Chertow
    • Vikram Fielding-Singh
    Now accepting new patients View Details
  • Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS

    This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a condition characterized by the abrupt, dramatic onset of obsessive compulsive disorder (OCD) and/or eating restriction accompanied by equally abrupt and severe co-morbid neuropsychiatric symptoms, which include anxiety, emotional lability, depression, irritability, aggression, oppositionality, deterioration in school performance, behavioral (developmental) regression, sensory amplification, movement abnormalities, sleep disturbance, and urinary frequency. PANS is thought to be caused by infection, inflammation, or alternate triggers that is associated with a brain response that leads to these symptoms. The purpose of this study is to examine specific neurologic, immunologic, rheumatologic, and genomic, components in children with the acute-onset of psychiatric symptoms. This research may begin to uncover a much larger story of autoimmune processes that are involved in psychiatric disorders of childhood. By better understanding the etiologic components of psychiatric phenomenon, future treatments may be better targeted to underlying causes.

    Investigator

    • Jennifer Frankovich
    Now accepting new patients View Details
  • NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

    Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.

    Investigators

    • Amelia Claire Watkins
    • Jason T. Lee, MD
    Now accepting new patients View Details
  • REHAB Fontan Failure: A Trial of Cardiac Rehabilitation

    The goal of this clinical trial is to compare the impact of cardiac rehabilitation on Fontan failure patients' exertional tolerance, frailty, and quality of life.

    1. Among patients with Fontan failure, will cardiac rehabilitation increase average daily steps compared to usual care?2. Among patients with Fontan failure, will cardiac rehabilitation improve exertional tolerance (as measured by cardiopulmonary exercise testing), frailty, and self-reported quality of life metrics compared to usual care?

    Investigator

    • Daniel Clark, MD, MPH
    Now accepting new patients View Details
  • Niclosamide in Pediatric Patients With Relapsed and Refractory AML

    Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

    Investigators

    • Adam Frymoyer
    • Norman J. Lacayo, MD
    • Kathleen M. Sakamoto
    Now accepting new patients View Details
  • HEAL-IST IDE Trial

    Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.

    Investigators

    • Albert "A.J." Rogers, MD, MBA, FAHA
    • Nitish Badhwar
    Now accepting new patients View Details
  • Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

    The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

    Investigator

    • Kevin M. Alexander, MD, FACC, FHFSA
    Now accepting new patients View Details
  • Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

    This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).

    The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

    Investigator

    • John W. Day, MD, PhD
    Now accepting new patients View Details
  • Prostate Cancer Upgrading Reference Set

    Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence of high grade cancer at time of prostatectomy (removal of prostate) among patients with a low grade cancer diagnosis at time of biopsy.

    Investigator

    • James D. Brooks
    Now accepting new patients View Details
  • Nerve Transfers Plus Electrical Stimulation to Improve Hand Function in Cervical Spinal Cord Injury

    The goal of this prospective observational study is to determine whether brief intraoperative electrical stimulation and temporary postoperative electrical stimulation improve motor and/or pain outcomes for patients with cervical spinal cord injury undergoing standard of care nerve transfer surgery to improve hand function.

    The main hypotheses include:

    Hypothesis #1: Brief intraoperative electrical stimulation of the donor nerves will result in improved motor outcomes (hand function) compared to standard nerve transfer surgery in patients with cervical spinal cord injuries.

    Hypothesis #2: Placement of a temporary peripheral nerve stimulator for 60 days of postoperative electrical stimulation will result in improved pain outcomes compared to standard nerve transfer surgery in patients with cervical spinal cord injuries.

    Researchers will prospectively enroll patients with cervical spinal cord injury and no hand function who will undergo standard of care nerve transfer surgery combined with standard of care brief intraoperative electrical stimulation and temporary postoperative electrical stimulation. Motor and pain outcomes will be compared to a retrospective group of patients who underwent nerve transfer surgery without intraoperative or postoperative electrical stimulation.

    Participants will receive standard medical care (nothing experimental) as part of this study. Participants will:

    * Have a preoperative assessment including physical examination, electrodiagnostic studies, functional electrical stimulation, and will complete questionnaires assessing function and quality of life* Agree upon a surgical plan, including the specific nerve transfers to be performed and whether to include brief intraoperative electrical stimulation and/or temporary postoperative electrical stimulation before being considered for enrollment in the study* Will undergo standard of care nerve transfer surgery, with at least one nerve transfer targeting improvement in hand function and will receive brief intraoperative electrical stimulation of the donor nerves and placement of a temporary peripheral nerve stimulator* Will follow-up with the surgeon 3, 6, 12, 24, and 36 months after the surgery* Will have a physical examination and will complete questionnaires at the postoperative visits* Will participate in hand therapy following the operation* Will be eligible for placement of a permanent peripheral nerve stimulator, depending on response to the temporary peripheral nerve stimulator.

    Investigator

    • Thomas J. Wilson
    Now accepting new patients View Details
  • MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans with Severe Posttraumatic Stress Disorder

    In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) in the treatment of posttraumatic stress disorder (PTSD). Through a randomized comparison of MDMA-aCPT versus Cognitive Processing Therapy (CPT), a VA gold standard treatment for PTSD, the proposed study will set the stage for understanding the potential use and application of MDMA-aCPT for PTSD within the VA system.

    Investigator

    • Trisha Suppes, MD, PhD
    Now accepting new patients View Details
  • Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

    This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).

    Investigator

    • Catherine Aftandilian
    Now accepting new patients View Details
  • North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

    The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.

    Investigator

    • Gregory Enns
    Now accepting new patients View Details
  • Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

    The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.

    Now accepting new patients View Details
  • Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

    While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer typically present with different molecular profiles from that of smokers, which results in prognostic and therapeutic implications. Molecular changes in NSCLC that have therapeutic significance include mutations in the epidermal growth factor receptor (EGFR) and rearrangements in the anaplastic lymphoma kinase (ALK) gene. These driver mutations typically are present in lung tumors found in never or light smokers.

    The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone, 12.3 vs. 10.3 months respectively. Results from the POINTBREAK trial demonstrated that carboplatin + pemetrexed + bevacizumab is an alternative option to carboplatin + paclitaxel + bevacizumab, with comparable survival but less toxicity. In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. The PD-1 inhibitor nivolumab and the PD-L1 inhibitor atezolizumab have shown prolonged survival in comparison to docetaxel in patients who previously progressed with chemotherapy, irrespective of PD-L1 expression. Thus, this study combines immunotherapeutic agent atezolozumab with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin and pemetrexed).

    Investigator

    • Heather Wakelee
    Now accepting new patients View Details
  • Preimplantation Genetic Testing in Women of Advanced Maternal Age

    The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.

    Investigator

    • Ruth Lathi, M.D.
    Now accepting new patients View Details
  • Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health

    In the U.S. it is recommended that children consume whole cow's milk (3.5% fat) from ages 1 to 2 years to support rapid early growth and brain development, and then at age 2 years transition to low-fat (1%) or non-fat milk to reduce saturated fat and calorie intake. To date, few studies have examined the optimal milk type for children to prevent obesity. This randomized controlled trial will evaluate the effect of consumption of whole versus 1% milk on child adiposity.

    Investigator

    • Anisha I Patel
    Now accepting new patients View Details
  • Imaging Synapses With [11C] UCB-J in the Human Brain

    The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by \[11C\]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.

    Investigator

    • Jong H. Yoon
    Now accepting new patients View Details
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next

Pediatric Dermatology Clinical Trials

No trials match your search ""

No trials match your search ""

No trials match your search ""

On this page

On this page

Ongoing & Upcoming Studies

Ongoing Studies

Upcoming Studies

Dermatology

Stanford Medicine

News

Careers

Contact

Health Care

Stanford Health Care

Stanford Children's Health

Stanford School of Medicine

About

Contact

Maps & Directions

Careers

Basic Science Departments

Clinical Science Departments

Academic Programs

Vision

Find People
Visit Stanford
Search Clinical Trials
Give a Gift
©2025 Stanford University
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • See us on Facebook
  • See us on X (Twitter)
  • Stanford University
  • Stanford School of Medicine
  • Stanford Health Care
  • Stanford Children's Health
  • Stanford Health Care Tri-Valley
  • Stanford Medicine Partners